Showing results (1-10 of 216) with videos related to
Sort By:
Pageof 22
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 1, 1996
[Methotrexate in gynecologic oncology]S Isonishi, Y TerashimaGan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1995
[Surgery in ovarian carcinoma]S Isonishi, Y TerashimaImmunology Letters|June 1, 1989
Antibody to poly(ADP-ribose) is an indicator of obstetric complications in pregnant patients with systemic lupus erythematosusY Kanai, S Isonishi, Y TerashimaOncology Reports|May 20, 2011
Tumor necrosis factor-alpha (TNF alpha) enhances cisplatin cytotoxicity to ovarian carcinoma xenograftsS Isonishi, S Shiotsuka, K Ochiai, et al.Asia-Oceania Journal of Obstetrics and Gynaecology|December 1, 1993
Maximal cytoreductive surgery and high dose cisplatin chemotherapy for advanced ovarian cancerK Ochiai, S Takakura, S Isonishi, et al.Asia-Oceania Journal of Obstetrics and Gynaecology|June 1, 1991
Effect of estrogen and progesterone on the growth of human ovarian dysgerminoma heterotransplanted to athymic nude miceK Ochiai, S Isonishi, Y Hirama, et al.International Journal of Oncology|May 12, 2011
Mechanism-related circumvention of Cisplatin resistance in human ovarian-carcinoma cells by (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanediacarboxylato)-platinum (ii) monohydrate and modulation of its sensitivity by 12-o-tetradecanoylphorbol-13-acetateS Isonishi, K Ochiai, M Yasuda, et al.Nihon Sanka Fujinka Gakkai Zasshi|January 1, 1991
[Cyclic high dose CAP therapy by short-stay admission for ovarian malignancies--to increase total dose of CDDP and to improve quality of life of patients]K Ochiai, S Isonishi, E Kimura, et al.Nihon Sanka Fujinka Gakkai Zasshi|July 1, 1985
[A study on factors influencing survival in stage I ovarian cancer]M Yasuda, Y Nakabayashi, S Isonishi, et al.Nihon Sanka Fujinka Gakkai Zasshi|December 1, 1987
Experimental endocrinotherapy with tamoxifen of human ovarian dysgerminoma transplanted into nude miceS IsonishiPageof 22